Lord Global (LRDG) 10-Q 22 Jun 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Apr. 30, 2020	Jun. 19, 2020
Document And Entity Information
Entity Registrant Name	Lord Global Corp
Entity Central Index Key	0001569568
Document Type	10-Q
Document Period End Date	Apr. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,280,755
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Apr. 30, 2020	Jul. 31, 2019
Current Assets
Cash	$ 161	$ 485
Total current assets	161	485
Fixed Assets
Equipment, net	850	1,181
Total Fixed Assets	850	1,181
Other Assets
Lord Global Goodwill	14,440
Website Development	5,500	5,500
Accumulated Amortization	(5,500)	(5,500)
Total Other Assets	14,440
Total Assets	15,451	1,666
Current liabilities
Accounts Payable	246,255	292,739
Advance from shareholders	63,886	75,135
Accrued Interest	51,475	88,640
Convertible Debt (net of unamortized discount)	125,654	97,153
Derivative Liability	231,755	224,809
Promissory note - related party	375,597	435,894
Total current liabilities	1,094,622	1,214,370
Total liabilities	1,160,479	1,214,370
Stockholders' deficit
Other convertible stock (see Note 5)	155,000
Common stock, $0.001 par value; 900,000,000 shares authorized, 1,056,700 and 44,333 issued and outstanding as of April 30, 2020 and July 31, 2019, respectively	4,853,114	4,433,279
Additional Paid In Capital	4,802,889	5,190,011
Accumulated deficit	(12,143,114)	(10,835,994)
Total stockholders' deficit	(1,079,171)	(1,212,704)
Total liabilities & stockholders' deficit	15,451	1,666
Series A Convertible Preferred Stock [Member]
Stockholders' deficit
Preferred stock value	1,200,000
Series L Convertible Preferred Stock [Member]
Stockholders' deficit
Preferred stock value	1,940
Series G Convertible Preferred Stock [Member]
Stockholders' deficit
Preferred stock value	50,000
Series F Convertible Preferred Stock [Member]
Stockholders' deficit
Preferred stock value	0
Series T Convertible Preferred Stock [Member]
Stockholders' deficit
Preferred stock value	0
Preferred Series B [Member]
Stockholders' deficit
Preferred stock value	1,000
Total stockholders' deficit	$ 1,000

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Apr. 30, 2020	Jul. 31, 2019
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	900,000,000	900,000,000
Common stock, shares issued	1,056,700	44,333
Common stock, shares outstanding	1,056,700	44,333
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,950	1,950
Preferred stock, shares issued	1	0
Preferred stock, shares outstanding	1	0
Series L Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20	20
Preferred stock, shares issued	18	0
Preferred stock, shares outstanding	18	0
Series G Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	60,000	60,000
Preferred stock, shares issued	550	0
Preferred stock, shares outstanding	550	0
Series F Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	40,000,000	40,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series T Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	375	375
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred Series B [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	1,000,000	0
Preferred stock, shares outstanding	1,000,000	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Income Statement [Abstract]
Revenue		$ 1,228	$ 619	$ 1,628
Operating expenses:
Professional fees	17,272	52,549	108,192	201,787
Expedition expenses		1,803	407	27,815
General and administrative	49,953	1,222	1,136,198	19,834
Total operating expenses	67,225	55,974	1,244,797	249,436
Net loss from operations	(67,225)	(54,746)	(1,244,178)	(247,808)
Other gain (loss)
Gain (loss) on settlement	332,592		262,592	15,042
Derivative gain (loss)		(40,657)	18,578	151,196
Loss on asset impairment	(280,100)		(280,100)
Interest expense	(7,111)	(113,786)	(56,902)	(258,741)
Total Other Income (Expense)	45,381	(154,443)	(55,832)	(92,503)
Net Loss	$ (21,844)	$ (209,189)	$ (1,300,010)	$ (340,311)
Basic and diluted loss per shares	$ (0.04)	$ (5.16)	$ (26.95)	$ (11.71)
Weighted average shares outstanding	554,336	40,540	48,223	29,066

Consolidated Statement of Chang

Consolidated Statement of Changes to Stockholders' Deficit (Unaudited) - USD ($)	Preferred Series B [Member]	Series A Preferred Stock [Member]	Preferred Series L [Member]	Preferred Series G [Member]	Preferred Series F [Member]	Preferred Series T [Member]	Other Convertibles [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Jul. 31, 2019								$ 4,433,279	$ 5,190,011	$ (10,835,994)	$ (1,212,704)
Balance, shares at Jul. 31, 2019								44,333
Stock issued for compensation or conversion								$ 419,834	(404,115)		15,719
Stock issued for compensation or conversion, shares								4,198
Stock issued for conversion of preferred series T
Stock issued for conversion of preferred series T, shares
Settlement of derivative liability									16,994		16,994
Net loss for the period ended										(1,202,543)	(1,202,543)
Balance at Oct. 31, 2019	$ 1,000	$ 1,200,000	$ 1,940					$ 4,853,113	4,802,890	(12,038,537)	(2,382,534)
Balance, shares at Oct. 31, 2019	1,000,000	1,950	18					48,531
Balance at Jul. 31, 2019								$ 4,433,279	5,190,011	(10,835,994)	(1,212,704)
Balance, shares at Jul. 31, 2019								44,333
Net loss for the period ended											(1,300,010)
Balance at Apr. 30, 2020	$ 1,000	$ 1,200,000	$ 1,940	$ 50,000	$ 1		$ 155,000	$ 4,853,117	4,802,887	(12,143,115)	(1,079,171)
Balance, shares at Apr. 30, 2020	1,000,000	1,950	18	550	10,000			55,971
Balance at Oct. 31, 2019	$ 1,000	$ 1,200,000	$ 1,940					$ 4,853,113	4,802,890	(12,038,537)	(2,382,534)
Balance, shares at Oct. 31, 2019	1,000,000	1,950	18					48,531
Stock issued for compensation or conversion								$ 3	(3)
Stock issued for compensation or conversion, shares								3,440
Net loss for the period ended										(82,734)	(82,734)
Balance at Jan. 31, 2020	$ 1,000	$ 1,200,000	$ 1,940					$ 4,853,116	4,802,887	(12,121,271)	(1,262,328)
Balance, shares at Jan. 31, 2020	1,000,000	1,950	18					51,971
Stock issued for compensation or conversion				$ 50,000	$ 1	$ 1	$ 155,000				205,002
Stock issued for compensation or conversion, shares				550	10,000	1,333
Stock issued for conversion of preferred series T						$ (1)		$ 1
Stock issued for conversion of preferred series T, shares						(1,333)		4,000
Net loss for the period ended										(21,844)	(21,844)
Balance at Apr. 30, 2020	$ 1,000	$ 1,200,000	$ 1,940	$ 50,000	$ 1		$ 155,000	$ 4,853,117	$ 4,802,887	$ (12,143,115)	$ (1,079,171)
Balance, shares at Apr. 30, 2020	1,000,000	1,950	18	550	10,000			55,971

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Cash flow from operating activities:
Net loss	$ (1,300,010)	$ (340,311)
Depreciation	331	443
Stock based compensation	1,081,000	36,249
(Gain) Loss on derivative liability	(18,578)	(151,196)
Amortization of debt discount	25,329	197,807
Debt penalties		17,364
Loss (gain) on debt settlement	(262,592)	(15,042)
Change in operating liabilities:
Accounts Receivable
Inventory
Accounts Payable	38,630	109,473
Accrued Interest	29,702	42,445
Net cash used in operating activities	(326,880)	(102,768)
Cash flow from investing activities
Cash Paid for Purchases of Fixed Assets
Lord Global Goodwill	(14,440)
Net cash used in investing activities	(14,440)
Cash flow from financing activities
Payment on Promissory Note	(59,456)	(36,477)
Proceeds from Convertible Debt, net of conversion	410,448	155,500
Issuance of Preferred Series L for acquisition	1,940
Repayment of Advance from shareholders	(186,220)	(79,909)
Proceeds for Advances from shareholders	174,284	74,864
Net cash provided by financing activities	340,996	113,978
Net increase in cash/(decrease)	(324)	11,210
Cash at beginning of period	485	587
Cash at end of period	161	11,797
Supplemental Cash Flow Information:
Cash paid for income taxes68
Cash paid for interest expense
Non-Cash Transactions:
Common stock issued for debt conversion	4,198	197,439
Recognition of derivative discount	38,578	172,270
Settlement of derivative liabilities		205,391
Discount on convertible notes		200,770
Cancellation of common stock	$ 45,008	$ 10,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 1 –SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Nature of Business and Trade Name A summary of significant accounting policies of Lord Global Corporation (the “Company”), a company organized in the state of Nevada, is presented to assist in understanding the Company’s financial statements. The accounting policies presented in these footnotes conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the companying financial statements. These financial statements and notes are representations of the Company’s management who are responsible for their integrity and objectivity. Lord Global Corporation (“we”, “our” the “Company”), formally known as Bigfoot Project Investments Inc. (“Bigfoot, Inc.” “Searching for Bigfoot, Inc.”), was incorporated in the State of Nevada on November 30, 2011. The Company’s principal address is 318 N Carson St, Suite 208, Carson City, Nevada 89701 and its fiscal year ends July 31. From its inception in 2011, the Company had been engaged in organizational efforts and the pursuit of financing its Bigfoot entertainment projects. In connection with its change in control in November 2019 (discussed below). The Company retained a 19% minority ownership stake in their predecessor Bigfoot Project Investments, Inc. upon finalization of transfer of ownership and name change to Lord Global Corporation. The Company, through 27Health, Inc., its wholly owned subsidiary organized in January 2020, has been engaged in providing services to and making strategic investments in revenue generating projects and entities in which it will take an active business role. The Company believes that one of its competitive advantages is the wide range of investment and management experience of the newly constituted Board. The Company will capitalize on the current and future projects through contractual agreements which allow the Company to continue to create and establish strategic alliances with other unaffiliated entities to generate revenues from its strategic investments and equity ownership interests. Reference is made to the disclosure under Note 8-SUBSEQUENT EVENTS, with respect to onging pursuit in furtherance of its plan of operations. On November 13, 2019, the former CEO Carmine T. Biscardi entered into a share purchase agreement with Lord Global Company and Joseph Cellura to sell 3,220 shares of Preferred Series A Convertible stock (pre-split) and 45,008 shares of common stock (post-split). This agreement transferred controlling interest of both the Preferred Series A (100% issued and outstanding) and common stock (51.16% issued and outstanding) effective November 27, 2019. As of the date of this Report, the former CEO Carmine T. Biscardi owns 0% of the outstanding Series A shares and less than 1% of the outstanding shares of common stock. On December 9, 2019, the standing Board of Directors held a meeting and elected a new officers and Board of Directors. All newly elected Officers will also serve on the Board of Directors. On December 31, 2019, the Company acquired a private Nevada based company named Lord Global Corporation. As part of the acquisition, the Company issued Preferred Series L stock to the shareholders of Lord Global Corporation in exchange for the shares held in proportion to the ownership percentages of the existing shareholders of the private corporation. On January 28, 2020, Lord Global Corporation (the private company) dissolved and 27Health Inc. took majority ownership control of the public company Lord Global Corporation. Subsequent to the acquisition, the Company applied to FINRA for an approval of a reverse stock split, a name change, and a ticker symbol change. FINRA approved the changes on January 28 th After the acquisition of Lord Global Corporation, the Company affected corporate actions involving: (i) reverse stock split on a 1:100,000 basis (the “Reverse Split”), (ii) a name change from Bigfoot Project Investments, Inc. to Lord Global Corporation (the “Name Change”), and (iii) the assignment of a new trading symbol “LRDG” (collectively, the “Corporate Actions”). On January 28, 2020, FINRA approved the Corporate Actions , with the implementation of the Reverse Split, Name Change, and assignment of LRDG as the new trading symbol. Unless specifically noted herein, references to share and per-share amounts give retroactive effect to the Reverse Stock Split. Basis of Presentation The accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim consolidated financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim consolidated financial statements. In the opinion of management such unaudited information includes all adjustments (consisting only of normal recurring accruals) necessary for a fair presentation of this interim information. Operating results and cash flows for interim periods are not necessarily indicative of the results that can be expected for the entire year. The information included in this report should be read in conjunction with our audited financial statements and notes thereto included in our 10-K for the year ended July 31, 2019 filed on SEC website on December 9, 2019. Revenue Recognition The Company accounts for revenues according to ASC Topic 606, “Revenue from Contracts with Customers” which establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts to provide goods or services to customers. The new standard’s core principal is that an entity will recognize revenue at an amount that reflects the consideration to which the entity expects to be entitled in exchange for transferring good or services to a customer. The principals in the standard are applied in five steps: 1) Identify the contract(s) with a customer; 2) Identify the performance obligations in the contract; 3) Determine the transaction price; 4) Allocate the transaction price to the performance obligations in the contract; and 5) Recognize revenue when (or as) the entity satisfies a performance obligation. During the nine months ended April 30, 2020 and 2019, the Company’s revenues were primarily made up of revenue generated from our online streaming distributor. The Company generated revenues from contracted sources of $619 and $1,628 for the nine months ended April 30, 2020 and 2019, respectively. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned or controlled operating subsidiaries. All intercompany accounts and transactions have been eliminated. Fair value of financial instruments The carrying value of cash, accounts receivable, accounts payable and accrued expenses, and debt approximate their fair values because of the short-term nature of these instruments. Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable. ● Level 1 - Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets. ● Level 2 - Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily-available pricing sources for comparable instruments. ● Level 3 - Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances. The following tables present the derivative financial instruments, the Company’s only financial liabilities measured and recorded at fair value on the Company’s balance sheets on a recurring basis, and their level within the fair value hierarchy as of April 30, 2020 and July 31, 2019: As of July 31, 2019 Amount Level 1 Level 2 Level 3 Embedded conversion derivative liability $ 177,746 $ - $ - $ 177,746 Warrant derivative liability 47,063 - 47,063 Total as of July 31, 2019 $ 224,809 $ - $ - $ 224,809 As of April 30, 2020 Embedded conversion derivative liability $ 184,809 $ - $ - $ 184,809 Warrant derivative liability 46,946 - - 46,946 Total as of April 30, 2020 $ 231,755 $ - $ - $ 231,755 The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs: Balance at July 31, 2018 $ 351,492 Fair value of derivative liability at issuance charged to debt discount 200,770 Fair value of derivative liability at issuance charged to derivative loss 128,880 Reclass to equity due to conversion (205,391 ) Write-off of derivative liability due to settlement (57,248 ) Unrealized derivative gain included in other expense (222,828 ) Balance at April 30, 2019 $ 195,675 Balance at July 31, 2019 $ 224,809 Fair value of derivative liability at issuance charged to debt discount 20,000 Fair value of derivative liability at issuance charged to derivative loss 97 Reclass to equity due to conversion (16,994 ) Unrealized derivative (gain) loss included in other expense 3,843 Balance at April 30, 2020 $ 231,755 The Company evaluated its convertible notes to determine if the embedded component of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The Company determined that due to the variable number of common stock that the notes convert to, the embedded conversion option were required to be bifurcated and accounted for as a derivative liability. The fair value of the derivative liability is calculated at the time of issuance and the Company records a derivative liability for the calculated value. Changes in the fair value of the derivative liability are recorded in other income (expense) in the consolidated statements of operations. Upon conversion of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Asset Impairment ASC Topic 360 requires that a company recognize an impairment loss if, and only if, the carrying amount of a long-lived asset (asset group) is not recoverable from the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset (the “Recoverable Amount”), and if the carrying amount exceeds the asset’s Fair Market Value. In the event the Company determines an asset is impaired, it is written off to the consolidated statement of operations as a non-operating loss in the period which Management deems the asset impairment occurred. During the nine months ended April 30, 2020, the Company made approximately $280,600 in cash payments to a related party for preservation and protection of the Company and its subsidiaries collateral interests, as well as its long-term strategic plan. Management accounted for this transaction by increasing both its capital investment in Bigfoot and also shareholder promissory note for the same amount. At April 30, 2020, the shareholder note had been forgiven and the investment in Bigfoot, Inc. was considered impaired. Because of the asset impairment, the entire balance of $280,000 was written off to the statement of income in the current period. Balance of this shareholder loan as of April 30, 2020 and July 31, 2019 was $0. Management has evaluated Accounting Standards Codification (“ASC”) topic 820 Fair Value Measurements and ASC topic 360 asset impairment over the approximately $280,000 capital contribution in its minority owned subsidiary Bigfoot, Inc. Due to results of the impairment analysis, the Company concluded that value associated to the approximate $280,000 capital contribution made to preserve and protect the Company’s collateral investment in Lord Global Corporation and minority owned subsidiary Bigfoot, Inc. is impaired. As a result of this analysis and determination, the Company wrote the entire amount of approximately $280,000 as a loss on asset impairment in the current period statement of income ending April 30, 2020. The Company retains a 19% minority ownership stake in subsidiary Bigfoot, Inc. as of the date of this Report. Management performs asset impairment analysis on at least a quarterly basis. The Company’s derivative instruments were valued using the Lattice model (for convertible notes) based on a probability weighted discounted cash flow model, and the Montel Carlo model (for tainted warrants) based on a multipath random event model. For the nine months ended April 30, 2020, assumptions used in the valuation include the following: a) underlying stock price ranging from $0.63 to $10.00 (post-reverse); b) projected discount on the conversion price ranging from 40.68% to 70.10% with the notes effectively converting at discounts in the range of 40% to 58%; c) projected volatility of 397.5% to 440.0%; d) probabilities related to default and redemption of the notes during the term of the notes, and e) current liquidity of the Company’s stock, daily average float, and so forth. For the nine months ended April 30, 2019, assumptions used in the valuation include the following: a) underlying stock price ranging from $30 to $160; b) projected discount on the conversion price ranging from 40% to 58% with the notes effectively converting at discounts in the range of 38.70% to 65.17%; c) projected volatility of 261.1% to 310.1%; d) probabilities related to default and redemption of the notes during the term of the notes. The Company has considered the provisions of ASC 480, Distinguishing Liabilities from Equity Basic and Diluted Earnings per Share Basic earnings per share are based on the weighted-average number of shares of common stock outstanding during the reporting period. The FASB ASC Topic 260, “Earnings per Share”, requires the Company to include additional shares in the computation of earnings per share, assuming dilution. Diluted earnings per share are based on the assumption that all dilutive options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options are assumed to be exercised at the time of issuance, and as if funds obtained thereby were used to purchase common stock at the average market price during the period. We calculate basic earnings (loss) per share by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share is calculated similarly but reflects the potential impact of outstanding stock options, stock warrants and other commitments to issue common stock, including shares issuable upon the conversion of convertible notes outstanding, except where the impact would be anti-dilutive. The following is a reconciliation of basic and diluted earnings per share for the three and nine months ended April 30, 2020 and 2019: Three Months Three Months Nine Months Nine Months April 30, 2020 April 30, 2019 April 30, 2020 April 30, 2019 Numerator: Net (loss) available to common shareholders $ (21,844 ) $ (209,189 ) $ (1,300,010 ) $ (340,311 ) Denominator: Weighted average shares – basic and diluted 554,335 40,540 368,417 29,064 Net (loss) per share – basic and diluted $ (0.04 ) $ (5.16 ) $ (3.53 ) $ (11.71 ) Reclassifications and adjustments Certain prior year amounts have been reclassified for consistency with the current year presentation and for proper presentation under GAAP. These reclassifications had no effect on the reported results of operations.

Going Concern

Going Concern	9 Months Ended
	Apr. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 2 - GOING CONCERN The Company’s consolidated financial statements are prepared using accounting principles generally accepted in the United States of American applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company does not have significant cash or other current assets, nor does it have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. These conditions raise substantial doubt about our ability to continue as a going concern. Under the going concern assumption, an entity is ordinarily viewed as continuing in business for the foreseeable future with neither the intention nor the necessity of liquidation, ceasing trading, or seeking protection from creditors pursuant to laws or regulations. Accordingly, assets and liabilities are recorded on the basis that the entity will be able to realize its assets and discharge its liabilities in the normal course of business. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plan described in the preceding paragraph and eventually attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that may be necessary if the Company is unable to continue as a going concern. Historically, the Company has mostly relied upon internally generated funds such as shareholder loans and advances to finance its operation and growth. Management may raise additional capital by future public or private offerings of the Company’s stock or through loans from government or private investors, although there can be no assurance that it will be able to obtain such financing. The Company’s failure to do so could have a material and adverse effect upon it and its stockholders.

Advance from Shareholders

Advance from Shareholders	9 Months Ended
	Apr. 30, 2020
Related Party Transactions [Abstract]
Advance from Shareholders	NOTE 3 – ADVANCE FROM SHAREHOLDERS In the nine months ended April 30, 2020, additional advances from shareholders were received in the amount of $204,520. The Company made payments on these advances amounting to $186,220. These advances bear no interest and are due on demand. In the nine months ended April 30, 2020, additional advances from shareholders were received in the amount of $74,759. The Company made payments on these advances amounting to $63,133. These advances bear no interest and are due on demand. Total advances from shareholders as of July 31, 2019 were $75,135 and as of April 30, 2019 were $52,479. Liability associated to the related party promissory note was taken by the Company’s wholly owned subsidiary Health Expedition Inc., and is therefore included in the Company’s balance sheet at April 30, 2020. The total advances from shareholders outstanding as of July 31, 2019 were $75,135 and as of April 30, 2020 were $0.

Note Payable - Related Party

Note Payable - Related Party	9 Months Ended
	Apr. 30, 2020
Related Party Transactions [Abstract]
Note Payable - Related Party	NOTE 4 – NOTE PAYABLE – RELATED PARTY In January 2013, Lord Global Corporation executed a promissory note in the amount of $484,029 as part of the asset transfer agreement for the transfer of all assets held by Searching for Bigfoot, Inc. In August 2013, the Company increased the balance of the promissory note by $489 to add an asset that was not included in the original transfer. The promissory note is subject to annual interest of 4%. The unpaid principal and the accrued interest were originally payable in full on January 31, 2019, then the maturity date was extended to January 31, 2020. During fiscal year 2020, the Company paid $9,456 against the promissory note balance, and issued the related party promissory note holder 5,000 shares of Series A Convertible Preferred stock (pre-split), 500 shares (post-split) of which were issued in exchange for $50,000 payment towards the related party promissory note principal balance (see Note 5). As of April 30, 2020, and July 31, 2019, the outstanding balance on the related party promissory note was $375,200 and $435,894, respectively. During fiscal year 2020, Liability associated to the related party promissory note was taken by the Company’s wholly owned subsidiary Health Expedition Inc., and is therefore included in the Company’s balance sheet at April 30, 2020. Interest expense for the Company, in total, during the nine months ended April 30, 2020 and 2019 was $64,013 and $258,741, respectively.

Capital Stock

Capital Stock	9 Months Ended
	Apr. 30, 2020
Equity [Abstract]
Capital Stock	NOTE 5 - CAPITAL STOCK Common Stock The holders of the Company’s common stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends at such times and in such amounts as the board from time to time may determine. Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. There is no cumulative voting of the election of directors then standing for election. The common stock is not entitled to pre-emptive rights and is not subject to conversion or redemption. Upon liquidation, dissolution or winding up of the company, the assets legally available for distribution to stockholders are distributable ratably among the holders of the common stock after payment of liquidation preferences, if any, on any outstanding payment of other claims of creditors. The Company has 1,056,700 and 44,333 shares of common stock issued and outstanding as of April 30, 2020 and July 31, 2019, respectively. During the nine months ended April 30, 2020, the Company designated four new classes of preferred stock, par value $0.001 (collectively, the “Preferred Stock”): Series F Convertible Preferred Stock with 40,000,000 shares authorized; Series T Convertible Preferred Stock with 375 shares authorized; Series B Super Voting Preferred with 1,000,000 shares authorized; and Series G Convertible Preferred with 60,000 shares authorized. During the nine months ended April 30, 2020, on February 7, 2020, the Company entered into a share exchange agreement with 27 Health, Inc., an entity controlled by the Company’s executive officers and directors, pursuant to which the Company acquired 100% of the capital stock of 27 Health in exchange for 10,000 shares of newly authorized Series F Preferred, which shares were issued in proportion to the ownership percentages of their 27 Health stock. Upon the issuance of the shares of Series F Preferred, 27 Health Inc. became a wholly owned subsidiary of Lord Global Corporation. The acquisition was recorded at the par value of the stock at the time of issuance. . During the nine months ended April 30, 2020, Auctus Fund LLC (“Auctus Fund”) issued a conversion notice for the loan executed on August 1, 2018 to the Company for 2,048 shares of common stock for a principal reduction of $2,917 interest of $4,776 update and fees of $500. During the nine months ended April 30, 2019, subsequent to the above conversion notice, the Company issued to Auctus Fund 1,103 shares of common stock to convert the principal amount due of $3,516 and settlement of unpaid interest of $83 and penalty of $10,000. During the nine months ended April 30, 2020, Crown Bridge Partners Fund LLC issued a conversion notice for the loan executed February 25, 2019 to the Company for 2,150 shares of common stock for a principal reduction of $6,775 and fees of $750. During the nine months ended April 30, 2019, the Company reserved 217 shares of common stock for Veyo Partners per the consulting agreement dated November 30, 2017. Fair value of the shares reserved as of January 31, 2020 is $8,647. During the nine months ended April 30, 2020, on November 8, 2019, 1,780 shares of Series A Convertible Preferred stock were converted to 42,720 shares of common stock by the former CEO Carmine T. Biscardi. During the nine months ended April 30, 2020, on November 13, 2019, the former CEO Carmine T. Biscardi entered into a share purchase agreement with Lord Global Corporation and Joseph Cellura to sell 3,220 shares of Preferred Series A Convertible stock and 45,008 shares of common stock (post-split). This agreement transferred controlling interest of both the Preferred Series A (100% issued and outstanding) and common stock (51.16% issued and outstanding) to these parties, effective and as of November 27, 2019. During the nine months ended April 30, 2020, on December 13, 2019, by vote of majority shareholders and unanimous consent of the Board, the Company approved a 100,000 to 1 reverse stock split. On December 16, 2019, the Company filed with the State of Nevada a Certificate of Change registering the 100,000 to 1 reverse stock split for each class of stock. The reverse stock split was approved by FINRA effective January 29, 2020. During the nine months ended April 30, 2020, the Company designated four new classes of preferred stock: Series F Convertible Preferred with 40,000,000 shares authorized at $0.001 par value, Series T Convertible Preferred with 375 shares authorized at $0.001 par value, Series B Super Voting Preferred with 1,000,000 shares authorized at $0.001 par value, and Series G Convertible Preferred with 60,000 shares authorized at $0.001 par value. During the nine months ended April 30, 2020, on February 7, 2020, the Company entered into a share exchange agreement with 27 Health, Inc. The issued shares of the acquired company will be exchanged for Preferred Series F stock in proportion to the ownership percentages of the issued stock. Upon the issuance of the stock, 27 Health Inc. will become a wholly owned subsidiary of Lord Global Corporation. The acquisition was recorded at the par value of the stock at the time of issuance. During the nine months ended April 30, 2020, Management returned to treasury 45,008 shares of common stock. During the nine months ended April 30, 2020, the Company issued 18 shares of Preferred Series L convertible stock as compensation for the share exchange agreement with Lord Global Corporation for approximately $1,940 in consideration. During the nine months ended April 30, 2020, the Company issued 1,000,000 shares of Preferred Series B Super Voting stock as compensation for on-going negotiations for acquisitions of revenue generating contracts and/or interests in third party entities. During the nine months ended April 30, 2020, the Company issued 550 shares of Preferred Series G convertible stock to CNLT LLC in exchange for approximately $50,000 cash consideration. Each Series G share converts to 1,000 shares of common stock. No of these shares were converted into common stock at April 30, 2020 or July 31, 2019. During the nine months ended April 30, 2020, JA Ventures, Inc. converted 1,000,000 shares of common stock as compensation for development of revenue generating contracts and previously held convertible preferred stock. Series A Convertible Preferred Stock During the nine months ended April 30, 2020, on October 31, 2019, the Company authorized 1,950 shares of the Series A Convertible Preferred Stock (“Series A Preferred”), pursuant to the Series A Certificate of Designation, which Series A Preferred shall be convertible into shares of common stock of the Company at the option of the holders thereof at any time. Each share of Series A Preferred is convertible into 24 shares of common stock. The Series A Convertible Preferred Stock has the following rights and privileges: Voting Conversion Liquidation Contingent redemption (i) the Company fails for any reason, including without limitation as a result of not having a sufficient number of shares of Common Stock authorized and reserved for issuance, or as a result of the limitation contained in the stock designation, or due to voluntary action undertaken by the Company or a failure by the Company to take action, to issue shares of Common Stock to a Holder and deliver certificates representing such shares to such Holder as and when required by the provisions hereof upon Conversion of any Preferred Shares, and such failure continues for ten (10) Business Days; (ii) the Company breaches, in a material respect, due to voluntary action undertaken by the Company or a failure by the Company to take action, any covenant or other material term or condition of the Preferred Stock, or any other agreement, document, certificate or other instrument delivered in connection with the transactions contemplated thereby, and such breach continues for a period of five (5) Business Days after written notice thereof to the Company from a Holder; (iii) any material representation or warranty made by the Company in any agreement, document, certificate or other instrument delivered in connection with the transactions contemplated hereby or thereby is inaccurate or misleading in any material respect as of the date such representation or warranty was made due to voluntary action undertaken by the Company or a failure by the Company to take action. The Board voted to award the CEO Carmine T. Biscardi 5,000 shares of Preferred Series A stock, of which 500 shares of Series A convertible preferred stock were issued in exchange for $50,000 of the debt and 4,500 shares of Series A convertible preferred stock were issued as compensation for his long service to the Company. We determined the fair value of the preferred stock as of the issuance date based on the market price of $10 for common stock with 1 share of Series A Preferred Stock convertible to 24 shares of common stock, resulting in a fair value of $240 per share. Thus, the fair value for 500 and 4,500 shares of Series A Convertible Preferred Stock is $120,000 and $1,080,000, respectively. The Company recognized a loss on settlement of debt of $70,000 and stock-based compensation of $1,080,000 for the above-mentioned preferred stock issuances, during the nine months ended April 30, 2020. Due to the Preferred Stock’s contingent redemption feature, the Series A Convertible Preferred Stock are reported as temporary equity in the consolidated balance sheet. Of the 5,000 shares of Series A Preferred stock issued, approximately 1,700 shares of Series A Preferred was outstanding at April 30, 2020 and 0 shares at July 31, 2019. Approximately 3,300 shares were converted to common stock by the stockholder. Series B Super Voting Preferred Stock During the nine months ended April 30, 2020, pursuant to the Certificate of Designation, the Company authorized 1,000,000 shares of Series B Super Voting Preferred Stock (“Series B Preferred”), which shall have non-dilutable voting rights equivalent to 68% of all voting shares. The Series B Super Voting Preferred Stock has the following rights and privileges: Voting Liquidation During the nine months ended April 30, 2020, the Company issued 1,000,000 shares of Series B Super Voting Preferred Stock to 27 Health, Inc. as compensation for on-going negotiations for revenue generating contracts. As of the date of this Report, no additional Series B Super Voting Preferred Stock shares are available to issue. Series G Convertible Preferred Stock During the nine months ended April 30, 2020, the Company authorized 60,000 shares of Series G Convertible Preferred Stock (“Series G Preferred”) pursuant to a Series G Certificate of Designation. The Series G Preferred Convertible Stock have, among other rights and privileges, the right to convert the shares of Series G Preferred into 1,000 shares of common stock. The Series G Preferred has, in addition to the above conversion rights, a beneficial ownership limitation provision which states, in substance, that in no event may a holder of shares of Series G Preferred convert into common stock a number of Series G Preferred if, as a result of such conversion, the holder would own in excess of 4.99% of the Company’s then outstanding shares of common stock. During the nine months ended April 30, 2020, on March 25, 2020, the Company issued 550 shares of Series G convertible preferred stock (“Series G Preferred”) to CNLT, LLC in exchange for approximately $330,000 cash consideration (see Note 1 and Note 4). None of these shares of Series G Preferred were converted into common stock as of April 30, 2020 or as of the date of this Report. See Note 8-Subsequent Events with respect to the issuance in May 2020 of 1,500 additional shares of Series G Preferred to an unrelated third party as part of a Settlement Agreement. Series L Convertible Preferred Stock During the nine months ending April 30, 2020, on January 17, 2019, pursuant to the Certificate of Designation, the Company authorized 20 shares of the Series L Convertible Preferred Stock (“Series L Preferred”), which shall be convertible into shares of common stock of the Company at the option of the holders thereof at any time after the issuance of the preferred stock. Each Series L Convertible Preferred Stock shall be converted into 3 shares of common stock. The Series L Convertible Preferred Stock has the following rights and privileges: Voting Conversion Liquidation Contingent redemption (i) the Company fails for any reason (including without limitation as a result of not having a sufficient number of shares of Common Stock authorized and reserved for issuance, or as a result of the limitation contained in the stock designation, or due to voluntary action undertaken by the Company or a failure by the Company to take action, to issue shares of Common Stock to a Holder and deliver certificates representing such shares to such Holder as and when required by the provisions hereof upon Conversion of any Preferred Shares, and such failure continues for ten (10) Business Days; (ii) the Company breaches, in a material respect, due to voluntary action undertaken by the Company or a failure by the Company to take action, any covenant or other material term or condition of the Preferred Stock, or any other agreement, document, certificate or other instrument delivered in connection with the transactions contemplated thereby, and such breach continues for a period of five (5) Business Days after written notice thereof to the Company from a Holder; (iii) any material representation or warranty made by the Company in any agreement, document, certificate or other instrument delivered in connection with the transactions contemplated hereby or thereby is inaccurate or misleading in any material respect as of the date such representation or warranty was made due to voluntary action undertaken by the Company or a failure by the Company to take action. During the nine months ended April 30, 2020, pursuant to the share exchange agreement with Lord Global Corporation dated December 31, 2019, the Company issued 1,940,000 shares of Preferred Series L stock in exchange for the outstanding shares of the private company. The stock has a stated par value of $0.001, the transaction was recorded at the stated par value of the stock. Series T Convertible Preferred Stock During the nine months ended April 30, 2020, on January 17, 2019, pursuant to the Certificate of Designation, the Company authorized 375 shares of Series T Convertible Preferred Stock, which shall be convertible into shares of common stock of the Company at the option of the holders thereof at any time after the issuance of the preferred stock. Each Series T Convertible Preferred Stock shall be converted into 3 shares of common stock. The Series T Convertible Preferred Stock has the following rights and privileges: Voting Conversion Liquidation Contingent redemption (i) the Company fails for any reason (including without limitation as a result of not having a sufficient number of shares of Common Stock authorized and reserved for issuance, or as a result of the limitation contained in the stock designation, or due to voluntary action undertaken by the Company or a failure by the Company to take action, to issue shares of Common Stock to a Holder and deliver certificates representing such shares to such Holder as and when required by the provisions hereof upon Conversion of any Preferred Shares, and such failure continues for ten (10) Business Days; (ii) the Company breaches, in a material respect, due to voluntary action undertaken by the Company or a failure by the Company to take action, any covenant or other material term or condition of the Preferred Stock, or any other agreement, document, certificate or other instrument delivered in connection with the transactions contemplated thereby, and such breach continues for a period of five (5) Business Days after written notice thereof to the Company from a Holder; (iii) any material representation or warranty made by the Company in any agreement, document, certificate or other instrument delivered in connection with the transactions contemplated hereby or thereby is inaccurate or misleading in any material respect as of the date such representation or warranty was made due to voluntary action undertaken by the Company or a failure by the Company to take action. During the nine months ended April 30, 2020, approximately 1,333 shares were issued during the year to two investors in exchange for bon fide management services. The 1,333 preferred shares were converted on April 8, 2020 into 4,000 shares of common stock. As of the date of this Report, no shares were issued or outstanding with respect to the Company’s Series T Convertible Preferred stock. Series F Convertible Preferred Stock During the nine months ended April 30, 2020, on February 7, 2020, the Company authorized 40,000,000 shares of Series F Convertible Preferred Stock (“Series F Preferred”) pursuant to the Series F Certificate of Designation, which was amended on April 27, 2020, without making any material change. As of April 30, 2020, and the date of this Report, 10,000 shares of Series F Preferred were outstanding, all of which are owned by the founders and former owners of 27 Health, Inc. The Series F Preferred has, among other rights, the right to convert the shares of Series F Preferred into 97% of the Company’s common stock on a fully diluted basis, which includes all shares of common stock underlying convertible notes or other securities, including preferred stock, convertible into shares of the Company’s common stock. The Series F Preferred a beneficial ownership limitation provision which states, in substance, that in no event may a holder of shares of Series F Preferred convert into common stock a number of Series F Preferred if, as a result of such conversion, the holder would own in excess of 4.99% of the Company’s then outstanding shares of common stock. During the nine months ended April 30, 2020, the Company entered into a share exchange agreement with the holders of 27 Health, Inc. pursuant to which the Company issued 10,000 shares of Series F Preferred in exchange for all of the capital stock of 27 Health, Inc. for development of revenue generating contracts to be valued. Upon the issuance of the shares of Series F Preferred, 27 Health Inc. became a wholly owned subsidiary of Lord Global Corporation. The acquisition was recorded at the par value of the stock at the time of issuance. Warrants On February 25, 2019, the Company issued Crown Bridge Partners LLC a Common Stock Purchase Warrant for 189 shares of common stock. The warrants have an exercise price of $350 per share and expiration date of February 25, 2024. These warrants were tainted by the variable notes and the fair value of $47,063 was accounted for as a derivative liability in accordance with ASC 815. During the nine months ended April 30, 2020, no warrants were granted, forfeited, expired or cancelled. As of April 30, 2020, there were 189 warrants outstanding with a weighted average exercise price of $350, a weighted average remaining expiration period of approximately 4.0 years and intrinsic value of zero.

Distribution Agreements

Distribution Agreements	9 Months Ended
	Apr. 30, 2020
Guarantees and Product Warranties [Abstract]
Distribution Agreements	NOTE 6 – DISTRIBUTION AGREEMENTS The Company’s predecessor, Bigfoot, entered into a Distribution Agreement on September 2, 2011 with the Bosko Group LLC providing them a non-exclusive right to market the sales of the Company’s DVD’s. The Distribution Agreement requires the Company to pay the Bosko Group LLC ten percent (10%) of the selling price of the DVD’s sold. This agreement remained in effect for a period of 4 years and has been automatically renewed for an additional 4 years with no limit on the number of times the agreement may be automatically renewed, unless either party gives notice to the other of its desire to terminate the Agreement at least sixty (60) days before expiration of the original or renewal term. In May 2017, the Company entered into two separate agreements (the “Re-Release”) with The Bosko Group LLC (the “Distributor”) to provide distribution and promotional services to the Company. The terms of the agreements provide for the following: a. Compensation to the Company for the Re-Release will be based on projected gross sales range and royalties for six existing DVD documentaries which will be offered into all distribution markets as a series with a new introduction narrated by Tom Biscardi. b. Compensation to the Company for the Distribution of new feature-length films is based on past performance of previous productions with up-front funding and projected royalties over all distribution channels. The Company completed production of the first of the new feature-length films in July 2017. The film was edited and released in August 2018 through various channels, and the Company is awaiting sales reports from the distribution company. On August 1, 2018, the Company, entered into a Securities Purchase Agreement (the Securities Purchase Agreement”) with an investor, pursuant to which the Company sold to the Investor a convertible promissory note in the principal amount of $110,000 (the “August 2018 Note”), for an aggregate purchase price of $100,000. The Company received $100,000 cash and recorded $10,000 as issuance cost. The August 2018 Note matures on May 1, 2019, bears interest rate of 10% per year payable on maturity date in cash or shares of common stock at the Company’s option (subject to certain conditions), and is convertible into shares of the Company’s common stock at the conversion price equal to the lower of (i) the closing sale price of the common stock on the principal market on the trading day immediately preceding the closing date, and (ii) 55% of either the lowest sale price for the common stock during the 20 consecutive trading days including and immediately preceding the conversion date. This note became convertible on issuance date and the variable conversion feature was accounted for as a derivative liability in accordance with ASC 815. The Company recorded an increase in the principal of $15,000 since the conversion price is less than $0.01. The August 2018 Note has an outstanding balance as of April 30, 2020 of $79,399, is in default and subject to annual interest of 24%. During fiscal year 2020, Liability associated to the related party promissory note was taken by the Company’s wholly owned subsidiary Health Expedition Inc., and is therefore included in the Company’s balance sheet at April 30, 2020.

Convertible Debt

Convertible Debt	9 Months Ended
	Apr. 30, 2020
Debt Disclosure [Abstract]
Convertible Debt	NOTE 7 – CONVERTIBLE DEBT On September 23, 2019, the Company entered into a convertible promissory note with KinerjaPay Corp. in the principal amount of $20,000 (the “KPAY Note”), which had a maturity date of March 23, 2020 and was in default as of April 30, 2020 (subject to maximum default interest rate allowed by law plus penalties). The KPAY Note bears an annual interest rate of 10% per year payable on maturity date in cash or shares of common stock at the Company’s option (subject to certain conditions), and is convertible into shares of common stock at the conversion rate equal to 50% multiplied by the Market Price, as defined in the KPAY Note, subject to penalties in the event of default. (see Note 8 – Subsequent Events, for details of the Settlement Agreement between the Company and KinerjaPay Corp. pursuant to which the KPAY Note including principal, interest and all default penalties were satisfied in full in consideration for the issuance of 50,000 shares of common stock and 1,500 shares of newly authorized Series G Convertible Preferred Stock). On February 25, 2019, the Company signed a convertible promissory note with Crown Bridge Partners, LLC for a principal sum of $165,000 to be funded in tranches (collectively, the “CBP Notes”). The first installment of $28,500 was received for the principal of $33,000 on March 1, 2019. The CBP Notes provide for an interest rate of 8% per annum and had a maturity date in February 2020. Crown Bridge has the right to convert the notes at any time, the note bears interest rate of 8% per year payable on maturity date in cash or shares of common stock at the Company’s option (subject to certain conditions), and is convertible into shares of the Company’s common stock at the conversion price which equals 50% multiplied by the lowest one trading price for the common stock during the 25 day trading day period ending on the last complete trading day prior to the conversion date. The note is convertible on issuance date and the variable conversion feature with a fair value of $56,216 was accounted for as a derivative liability in accordance with ASC 815 with a corresponding charge of $28,500 to debt discount and $27,716 to day one loss on derivative. On February 25, 2019, the Company also issued Crown Bridge Partners LLC a Common Stock Purchase Warrant exercisable to purchase 18,857,142 pre-Reverse Split shares of common stock. The CBP Warrants have an exercise price of $0.0035 per share on a pre-Reverse Split basis, which CBP have an expiration date of February 25, 2024. These CBP Warrants were tainted by the variable conversion prices on the CBP Notes and the fair value of $47,063 was accounted for as a derivative liability in accordance with ASC 815. The outstanding balance of the principal on the note as of July 31, 2019 and April 30, 2020, is $33,000 and $26,225, respectively. On February 25, 2019, the Company signed a convertible promissory note with Crown Bridge Partners, LLC for a principal sum of $165,000 to be requested in installments. The first installment of $28,500 was received for the principal of $33,000 on March 1 st On March 2, 2020, the Company, entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with a third-party accredited investor, pursuant to which the Company issued to the Investor a convertible promissory note in the principal amount of $125,000 (the “March 2020 Note”), for an aggregate purchase price of $110,000. The Company received $110,000 cash and recorded $10,000 as issuance cost. The March 2020 Note matures on January 2, 2021, bears interest rate of 12% per year payable on maturity date in cash or shares of common stock at the Company’s option (subject to certain conditions), and is convertible into shares of the Company’s common stock at the conversion price equal to the lower of (i) the closing sale price of the common stock on the principal market on the trading day immediately preceding the closing date, and (ii) 55% of either the lowest sale price for the common stock during the 20 consecutive trading days including and immediately preceding the conversion date. During the nine months ended April 30, 2020, Crown Bridge Partners, LLC converted their promissory note investment into common stock. The outstanding principal balance on the note as of July 31, 2019 and April 30, 2020, is $33,000 and $26,225, respectively. The remaining balance of the loan was recorded as a gain on settlement of debt in the current period. During the three months ended April 30, 2020, the Company issued a convertible note to Auctus Fund, LLC, an unaffiliated, third-party accredited investor in the principal amount of $155,000. Auctus Fund may convert the Note into shares of common stock ata conversion price equal to a 40% discount the lowest sale price for the common stock during the 20 consecutive trading days including and immediately preceding the conversion date. In the nine months ended April 30, 2020 and 2019, the Company recorded amortization of debt discount in the amount of $45,936 and $120,438, respectively. Unamortized discount as of April 30, 2020 amounted to $0.

Subsequent Events

Subsequent Events	9 Months Ended
	Apr. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 8 - SUBSEQUENT EVENTS In May 2020, the Company applied for a promissory term loan note agreement with the United States Small Business Administration (“SBA Loan”). Terms of the SBA Loan are approximately $150,000 principal repaid over 30 years at approximately a 3% fixed interest rate. Proceeds of the SBA Loan will be used for working capital business requirements at discretion of Management and on behalf of stockholders. During May 2020, 6,000 shares of common stock were issued to Crown Bridge Partners LLC under their previously granted preferred stock warrant conversion option. During May 2020, in connection with the execution of a Settlement Agreement between the Company and KinerjaPay Corp., an unaffiliated third party (“KPAY”), the Company issued to KPAY 50,000 shares of common stock and 1,500 shares of Series G Convertible Preferred Stock (“Series G Preferred”), each of which is convertible into 1,000 shares of common stock. Pursuant to the Settlement Agreement, the 50,000 shares of common stock and 1,500 shares of Series G Preferred were issued in exchange for full consideration and satisfaction of payment of KPAY’s convertible note balance outstanding principal, accrued unpaid interest, and penalties, collectively, as of the date of conversion. The outstanding balance of the convertible promissory note prior to conversion including unpaid interest and penalties was approximately $50,000. On May 5, 2020, the Company entered into a non-binding letter of intent (“LOI”) with eWellness Healthcare Corporation, OTCQB: EWLL (“EWLL”), a copy of which was attached as Exhibit 10.1 to the subject Form 8-K. The parties agreed, subject to the execution of a definitive agreement (“Definitive Agreement”), that the Company: (i) will issue to EWLL shares of a newly authorized series of preferred stock (the “New LRDG Preferred Stock”) which will be convertible into a total of 2,000,000 shares of the Company’s common stock, subject to a 4.99% “blocker” or beneficial ownership limitation; (ii) will create a U.S. marketing entity for EWLL’s PHZIO and MSK360 telemedicine physical therapy operations to independent contractors an “gig” economy workers; (iii) will provide initial funding in an amount of $250,000 on or about May 15, 2020; (iv) will provide additional funding in an amount equal to 50% of the convertible note financing transactions entered into by the Company during the 12-month period from the execution of the Definitive Agreement, which will occur only after EWLL’s pending registration statement on Form S-1 is declared effective by the SEC; and (v) plans on filing a registration statement after execution of the Definitive Agreement for the registration, issuance and sale of the Company of the Company’s equity securities for the benefit and funding of EWLL’s growing operations. The foregoing are referred to collectively, as the “LRDG Obligations”), all of which are subject to the execution of the Definitive Agreement, after customary due diligence. In consideration for the Company’s fulfilment of their LRDG Obligations, EWLL has agreed, subject to the execution of the Definitive Agreement, to: (i) pay to LRDG 10% of the commissions generated by EWLL from the fees paid to EWLL by the independent contractors and “gig” workers using the EWLL’s PHZIO and MSK360 platform in their physical therapy practices; and (ii) the assignment to the Company by EWLL of 25% of EWLL’s cash flow from its revenue stream (“EWLL’s Cash Flow”), payable in arrears on a quarterly basis, commencing on the execution of the Definitive Agreement. The foregoing are referred to, collectively, as the “EWLL Obligations.” The parties have agreed that during the 1-year period following execution of the Definitive Agreement that EWLL shall have the right to repurchase up to 20% of EWLL’s Cash Flow in consideration for the repayment of 150% of funding provided EWLL by the Company from its convertible note financing transactions. The parties further agreed that if the Company does not provide EWLL $250,000 in initial funding by or about May 20, 2020, either party may terminate this non-binding LOI the respective LRDG Obligations and EWLL Obligations shall be deemed null and void. Reference is made to the Company’s Form 8-K filed on May 11, 2020 with respect to the LOI with EWLL. Negotiations for a Definitive Agreement are continuing. During June 2020, 54,355 shares of common stock were issued to the Auctus Fund under their granted preferred stock conversion option. During June 2020, 55,500 shares of common stock were issued to Crown Bridge Partners LLC under their granted preferred stock conversion option. During June 2020, 58,200 shares of common stock were issued to the Auctus Fund under their granted preferred stock conversion option. During June 2020, in exchange for services associated with development of revenue generating contracts, the Company issued CNLT 950 shares of Series G Convertible Preferred Stock. These Series G shares issued were in addition to to 550 shares of Series G Preferred issued in March 2020, for a total of 1,500 Series G shares issued to CNLT as of the date of this Report. As noted above, the Company issued 1,500 shares of series B Preferred to KinerjaPay in May 2020 pursuant to the Settlement Agreement. Each share of Series G Convertible Preferred Stock is convertible into 1,000 shares of common stock. Collectively, up to 3,000,000 shares of common stock are issuable upon conversion of the Series G Preferred, subject to as of the date of this Report. The Series G Preferred has, in addition to the above conversion rights, a beneficial ownership limitation provision which states, in substance, that in no event may a holder of shares of Series G Preferred convert into common stock a number of Series G Preferred if, as a result of such conversion, the holder would own in excess of 4.99% of the Company’s then outstanding shares of common stock. On June 18, 2020, 27Health, Inc, (“27Health”), a wholly owned subsidiary of the Company, entered into a Definitive Joint Venture Investment and Marketing Agreement with Coviguard, Inc. (“CoviGuard”), a copy of which was attached as Exhibit 10.20 to the Company’s Form 8-K filed on June 19, 2019 (the “Coviguard Agreement”). Coviguard is a private company that has developed and plans to market its unique, patent pending, oral spray and mouthwash, a product line designed for the purpose eliminating the CO-SAR2 (COVID-19) viral load in the mouth (the “Covi-Guard™ Products”). Reference is made to the Coviguard PowerPoint Presentation, attached as Exhibit 10.21 to the June 19, 2020 Form 8-K. Pursuant to the terms of the Coviguard Agreement, 27Health agreed to invest up to $100,000 in Coviguard for the production of the Covi-Guard™ Products, including an initial advance of $20,000 for the purpose of manufacturing prototypes. In addition, the Company has agreed, as partial consideration for Coviguard granting 27Health exclusive marketing rights to Covi-Guard™ Products, to issue 1,000,000 restricted shares of LRDG’s common stock, par value $0.001 (the “Shares” or “Common Stock”) in the name of Lisa Marie Kao, the principal and owner of Coviguard, subject to the terms and conditions set forth in the Coviguard Agreement. The parties further agreed that: (i) net revenues from the sale of Covi-Guard™ Products (other than revenues from the professional dental market), after manufacturing costs and other variable costs, shall be allocated 75% to 27Health and 25% to Coviguard or Lisa Marie Kao, at the discretion of Ms. Kao; (ii) net revenues, after expenses, from sales to the professional dental market, shall be 65% to 27Health and 35% to Coviguard or Lisa Marie Kao; (iii) after receipt by Lisa Marie Kao of $1,000,000 from the sale of the Shares, Ms. Kao shall invest any excess above $1,000,000 to purchase additional restricted shares of LRDG Common Stock from the Company at a price equal to 75% of the average closing bid price of such Shares during the twenty (20) trading days prior to the date of her reinvestment; and (iv) 27Health shall utilize the proceeds from Ms. Kao’s reinvestment for marketing and promotion of the Covi-Guard™ Products. Reference is made to the Company’s Form 8-K filed on June 19, 2020 and specifically to Exhibit 10.20 for complete terms and conditions of the Coviguard Agreement and to Exhibit 10.21, the recently published Coviguard PowerPoint Presentation. The Company, through 27Health, is actively pursuing agreements and strategic relationships, particularly in the health related industry for the purposes of generating revenues and positive cash flow from operations.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Organization, Nature of Business and Trade Name	Organization, Nature of Business and Trade Name A summary of significant accounting policies of Lord Global Corporation (the “Company”), a company organized in the state of Nevada, is presented to assist in understanding the Company’s financial statements. The accounting policies presented in these footnotes conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the companying financial statements. These financial statements and notes are representations of the Company’s management who are responsible for their integrity and objectivity. Lord Global Corporation (“we”, “our” the “Company”), formally known as Bigfoot Project Investments Inc. (“Bigfoot, Inc.” “Searching for Bigfoot, Inc.”), was incorporated in the State of Nevada on November 30, 2011. The Company’s principal address is 318 N Carson St, Suite 208, Carson City, Nevada 89701 and its fiscal year ends July 31. From its inception in 2011, the Company had been engaged in organizational efforts and the pursuit of financing its Bigfoot entertainment projects. In connection with its change in control in November 2019 (discussed below). The Company retained a 19% minority ownership stake in their predecessor Bigfoot Project Investments, Inc. upon finalization of transfer of ownership and name change to Lord Global Corporation. The Company, through 27Health, Inc., its wholly owned subsidiary organized in January 2020, has been engaged in providing services to and making strategic investments in revenue generating projects and entities in which it will take an active business role. The Company believes that one of its competitive advantages is the wide range of investment and management experience of the newly constituted Board. The Company will capitalize on the current and future projects through contractual agreements which allow the Company to continue to create and establish strategic alliances with other unaffiliated entities to generate revenues from its strategic investments and equity ownership interests. Reference is made to the disclosure under Note 8-SUBSEQUENT EVENTS, with respect to onging pursuit in furtherance of its plan of operations. On November 13, 2019, the former CEO Carmine T. Biscardi entered into a share purchase agreement with Lord Global Company and Joseph Cellura to sell 3,220 shares of Preferred Series A Convertible stock (pre-split) and 45,008 shares of common stock (post-split). This agreement transferred controlling interest of both the Preferred Series A (100% issued and outstanding) and common stock (51.16% issued and outstanding) effective November 27, 2019. As of the date of this Report, the former CEO Carmine T. Biscardi owns 0% of the outstanding Series A shares and less than 1% of the outstanding shares of common stock. On December 9, 2019, the standing Board of Directors held a meeting and elected a new officers and Board of Directors. All newly elected Officers will also serve on the Board of Directors. On December 31, 2019, the Company acquired a private Nevada based company named Lord Global Corporation. As part of the acquisition, the Company issued Preferred Series L stock to the shareholders of Lord Global Corporation in exchange for the shares held in proportion to the ownership percentages of the existing shareholders of the private corporation. On January 28, 2020, Lord Global Corporation (the private company) dissolved and 27Health Inc. took majority ownership control of the public company Lord Global Corporation. Subsequent to the acquisition, the Company applied to FINRA for an approval of a reverse stock split, a name change, and a ticker symbol change. FINRA approved the changes on January 28 th After the acquisition of Lord Global Corporation, the Company affected corporate actions involving: (i) reverse stock split on a 1:100,000 basis (the “Reverse Split”), (ii) a name change from Bigfoot Project Investments, Inc. to Lord Global Corporation (the “Name Change”), and (iii) the assignment of a new trading symbol “LRDG” (collectively, the “Corporate Actions”). On January 28, 2020, FINRA approved the Corporate Actions , with the implementation of the Reverse Split, Name Change, and assignment of LRDG as the new trading symbol. Unless specifically noted herein, references to share and per-share amounts give retroactive effect to the Reverse Stock Split.
Basis of Presentation	Basis of Presentation The accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim consolidated financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim consolidated financial statements. In the opinion of management such unaudited information includes all adjustments (consisting only of normal recurring accruals) necessary for a fair presentation of this interim information. Operating results and cash flows for interim periods are not necessarily indicative of the results that can be expected for the entire year. The information included in this report should be read in conjunction with our audited financial statements and notes thereto included in our 10-K for the year ended July 31, 2019 filed on SEC website on December 9, 2019.
Revenue Recognition	Revenue Recognition The Company accounts for revenues according to ASC Topic 606, “Revenue from Contracts with Customers” which establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts to provide goods or services to customers. The new standard’s core principal is that an entity will recognize revenue at an amount that reflects the consideration to which the entity expects to be entitled in exchange for transferring good or services to a customer. The principals in the standard are applied in five steps: 1) Identify the contract(s) with a customer; 2) Identify the performance obligations in the contract; 3) Determine the transaction price; 4) Allocate the transaction price to the performance obligations in the contract; and 5) Recognize revenue when (or as) the entity satisfies a performance obligation. During the nine months ended April 30, 2020 and 2019, the Company’s revenues were primarily made up of revenue generated from our online streaming distributor. The Company generated revenues from contracted sources of $619 and $1,628 for the nine months ended April 30, 2020 and 2019, respectively.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned or controlled operating subsidiaries. All intercompany accounts and transactions have been eliminated.
Fair Value of Financial Instruments	Fair value of financial instruments The carrying value of cash, accounts receivable, accounts payable and accrued expenses, and debt approximate their fair values because of the short-term nature of these instruments. Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable. ● Level 1 - Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets. ● Level 2 - Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily-available pricing sources for comparable instruments. ● Level 3 - Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances. The following tables present the derivative financial instruments, the Company’s only financial liabilities measured and recorded at fair value on the Company’s balance sheets on a recurring basis, and their level within the fair value hierarchy as of April 30, 2020 and July 31, 2019: As of July 31, 2019 Amount Level 1 Level 2 Level 3 Embedded conversion derivative liability $ 177,746 $ - $ - $ 177,746 Warrant derivative liability 47,063 - 47,063 Total as of July 31, 2019 $ 224,809 $ - $ - $ 224,809 As of April 30, 2020 Embedded conversion derivative liability $ 184,809 $ - $ - $ 184,809 Warrant derivative liability 46,946 - - 46,946 Total as of April 30, 2020 $ 231,755 $ - $ - $ 231,755 The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs: Balance at July 31, 2018 $ 351,492 Fair value of derivative liability at issuance charged to debt discount 200,770 Fair value of derivative liability at issuance charged to derivative loss 128,880 Reclass to equity due to conversion (205,391 ) Write-off of derivative liability due to settlement (57,248 ) Unrealized derivative gain included in other expense (222,828 ) Balance at April 30, 2019 $ 195,675 Balance at July 31, 2019 $ 224,809 Fair value of derivative liability at issuance charged to debt discount 20,000 Fair value of derivative liability at issuance charged to derivative loss 97 Reclass to equity due to conversion (16,994 ) Unrealized derivative (gain) loss included in other expense 3,843 Balance at April 30, 2020 $ 231,755 The Company evaluated its convertible notes to determine if the embedded component of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The Company determined that due to the variable number of common stock that the notes convert to, the embedded conversion option were required to be bifurcated and accounted for as a derivative liability. The fair value of the derivative liability is calculated at the time of issuance and the Company records a derivative liability for the calculated value. Changes in the fair value of the derivative liability are recorded in other income (expense) in the consolidated statements of operations. Upon conversion of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.
Asset Impairment	Asset Impairment ASC Topic 360 requires that a company recognize an impairment loss if, and only if, the carrying amount of a long-lived asset (asset group) is not recoverable from the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset (the “Recoverable Amount”), and if the carrying amount exceeds the asset’s Fair Market Value. In the event the Company determines an asset is impaired, it is written off to the consolidated statement of operations as a non-operating loss in the period which Management deems the asset impairment occurred. During the nine months ended April 30, 2020, the Company made approximately $280,600 in cash payments to a related party for preservation and protection of the Company and its subsidiaries collateral interests, as well as its long-term strategic plan. Management accounted for this transaction by increasing both its capital investment in Bigfoot and also shareholder promissory note for the same amount. At April 30, 2020, the shareholder note had been forgiven and the investment in Bigfoot, Inc. was considered impaired. Because of the asset impairment, the entire balance of $280,000 was written off to the statement of income in the current period. Balance of this shareholder loan as of April 30, 2020 and July 31, 2019 was $0. Management has evaluated Accounting Standards Codification (“ASC”) topic 820 Fair Value Measurements and ASC topic 360 asset impairment over the approximately $280,000 capital contribution in its minority owned subsidiary Bigfoot, Inc. Due to results of the impairment analysis, the Company concluded that value associated to the approximate $280,000 capital contribution made to preserve and protect the Company’s collateral investment in Lord Global Corporation and minority owned subsidiary Bigfoot, Inc. is impaired. As a result of this analysis and determination, the Company wrote the entire amount of approximately $280,000 as a loss on asset impairment in the current period statement of income ending April 30, 2020. The Company retains a 19% minority ownership stake in subsidiary Bigfoot, Inc. as of the date of this Report. Management performs asset impairment analysis on at least a quarterly basis. The Company’s derivative instruments were valued using the Lattice model (for convertible notes) based on a probability weighted discounted cash flow model, and the Montel Carlo model (for tainted warrants) based on a multipath random event model. For the nine months ended April 30, 2020, assumptions used in the valuation include the following: a) underlying stock price ranging from $0.63 to $10.00 (post-reverse); b) projected discount on the conversion price ranging from 40.68% to 70.10% with the notes effectively converting at discounts in the range of 40% to 58%; c) projected volatility of 397.5% to 440.0%; d) probabilities related to default and redemption of the notes during the term of the notes, and e) current liquidity of the Company’s stock, daily average float, and so forth. For the nine months ended April 30, 2019, assumptions used in the valuation include the following: a) underlying stock price ranging from $30 to $160; b) projected discount on the conversion price ranging from 40% to 58% with the notes effectively converting at discounts in the range of 38.70% to 65.17%; c) projected volatility of 261.1% to 310.1%; d) probabilities related to default and redemption of the notes during the term of the notes. The Company has considered the provisions of ASC 480, Distinguishing Liabilities from Equity
Basic and Diluted Earnings Per Share	Basic and Diluted Earnings per Share Basic earnings per share are based on the weighted-average number of shares of common stock outstanding during the reporting period. The FASB ASC Topic 260, “Earnings per Share”, requires the Company to include additional shares in the computation of earnings per share, assuming dilution. Diluted earnings per share are based on the assumption that all dilutive options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options are assumed to be exercised at the time of issuance, and as if funds obtained thereby were used to purchase common stock at the average market price during the period. We calculate basic earnings (loss) per share by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share is calculated similarly but reflects the potential impact of outstanding stock options, stock warrants and other commitments to issue common stock, including shares issuable upon the conversion of convertible notes outstanding, except where the impact would be anti-dilutive. The following is a reconciliation of basic and diluted earnings per share for the three and nine months ended April 30, 2020 and 2019: Three Months Three Months Nine Months Nine Months April 30, 2020 April 30, 2019 April 30, 2020 April 30, 2019 Numerator: Net (loss) available to common shareholders $ (21,844 ) $ (209,189 ) $ (1,300,010 ) $ (340,311 ) Denominator: Weighted average shares – basic and diluted 554,335 40,540 368,417 29,064 Net (loss) per share – basic and diluted $ (0.04 ) $ (5.16 ) $ (3.53 ) $ (11.71 )
Reclassifications and adjustments	Reclassifications and adjustments Certain prior year amounts have been reclassified for consistency with the current year presentation and for proper presentation under GAAP. These reclassifications had no effect on the reported results of operations.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Schedule of Fair Value, Liabilities Measured on Recurring Basis	The following tables present the derivative financial instruments, the Company’s only financial liabilities measured and recorded at fair value on the Company’s balance sheets on a recurring basis, and their level within the fair value hierarchy as of April 30, 2020 and July 31, 2019: As of July 31, 2019 Amount Level 1 Level 2 Level 3 Embedded conversion derivative liability $ 177,746 $ - $ - $ 177,746 Warrant derivative liability 47,063 - 47,063 Total as of July 31, 2019 $ 224,809 $ - $ - $ 224,809 As of April 30, 2020 Embedded conversion derivative liability $ 184,809 $ - $ - $ 184,809 Warrant derivative liability 46,946 - - 46,946 Total as of April 30, 2020 $ 231,755 $ - $ - $ 231,755
Schedule of Changes in Fair Value of Derivative Liability	The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs: Balance at July 31, 2018 $ 351,492 Fair value of derivative liability at issuance charged to debt discount 200,770 Fair value of derivative liability at issuance charged to derivative loss 128,880 Reclass to equity due to conversion (205,391 ) Write-off of derivative liability due to settlement (57,248 ) Unrealized derivative gain included in other expense (222,828 ) Balance at April 30, 2019 $ 195,675 Balance at July 31, 2019 $ 224,809 Fair value of derivative liability at issuance charged to debt discount 20,000 Fair value of derivative liability at issuance charged to derivative loss 97 Reclass to equity due to conversion (16,994 ) Unrealized derivative (gain) loss included in other expense 3,843 Balance at April 30, 2020 $ 231,755
Schedule of Reconciliation of Basic and Diluted Earnings Per Share	The following is a reconciliation of basic and diluted earnings per share for the three and nine months ended April 30, 2020 and 2019: Three Months Three Months Nine Months Nine Months April 30, 2020 April 30, 2019 April 30, 2020 April 30, 2019 Numerator: Net (loss) available to common shareholders $ (21,844 ) $ (209,189 ) $ (1,300,010 ) $ (340,311 ) Denominator: Weighted average shares – basic and diluted 554,335 40,540 368,417 29,064 Net (loss) per share – basic and diluted $ (0.04 ) $ (5.16 ) $ (3.53 ) $ (11.71 )

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Nov. 13, 2019	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019	Jul. 31, 2019
Date of incorporation				Nov. 30, 2011
Reverse stock split, description				Reverse stock split on a 1:100,000 basis.
Revenues from contracted sources			$ 1,228	$ 619	$ 1,628
Shareholder loan		$ 0		$ 0		$ 0
Minimum [Member]
Conversion price ratio				0.4068	0.40
Minimum [Member] | Discount Rate [Member]
Fair value inputs, percentage				40.00%	38.70%
Minimum [Member] | Projected Volatility [Member]
Fair value inputs, percentage				397.50%	261.10%
Maximum [Member]
Conversion price ratio				0.7010	0.58
Maximum [Member] | Discount Rate [Member]
Fair value inputs, percentage				58.00%	65.17%
Maximum [Member] | Projected Volatility [Member]
Fair value inputs, percentage				440.00%	310.10%
Post-reverse [Member] | Minimum [Member]
Stock price		$ 0.63	$ 30	$ 0.63	$ 30
Post-reverse [Member] | Maximum [Member]
Stock price		$ 10	$ 160	$ 10	$ 160
Bigfoot Project Investments, Inc. [Member]
Asset impairment charges				$ 280,000
Written off asset impairment				280,000
Related Party [Member]
Asset impairment charges				280,600
Written off asset impairment				$ 280,000
Share Purchase Agreement [Member] | Carmine T. Biscardi [Member]
Non controlling interest description	As of the date of this Report, the former CEO Carmine T. Biscardi owns 0% of the outstanding Series A shares and less than 1% of the outstanding shares of common stock.
Share Purchase Agreement [Member] | Series A Convertible Preferred Stock [Member]
Sale of shares	3,220
Non controlling interest rate	100.00%
Share Purchase Agreement [Member] | Common Stock [Member]
Sale of shares	45,008
Non controlling interest rate	51.16%
Bigfoot Project Investments, Inc. [Member]
Minority ownership interest		19.00%		19.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details) - USD ($)	Apr. 30, 2020	Jul. 31, 2019	Apr. 30, 2019	Jul. 31, 2018
Embedded conversion derivative liability	$ 184,809	$ 177,746
Warrant derivative liability	46,946	47,063
Total	231,755	224,809	$ 195,675	$ 351,492
Level 1 [Member]
Embedded conversion derivative liability
Warrant derivative liability
Total
Level 2 [Member]
Embedded conversion derivative liability
Warrant derivative liability
Total
Level 3 [Member]
Embedded conversion derivative liability	184,809	177,746
Warrant derivative liability	46,946	47,063
Total	$ 231,755	$ 224,809

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Derivative Liability (Details) - USD ($)	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Accounting Policies [Abstract]
Fair value of convertible debt, beginning balance	$ 224,809	$ 351,492
Fair value of derivative liability at issuance charged to debt discount	20,000	200,770
Fair value of derivative liability at issuance charged to derivative loss	97	128,880
Reclass to equity due to conversion	(16,994)	(205,391)
Write-off of derivative liability due to settlement		(57,248)
Unrealized derivative (gain) loss included in other expense	3,843	(222,828)
Fair value of convertible debt, ending balance	$ 231,755	$ 195,675

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Reconciliation of Basic And Diluted Earnings Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Accounting Policies [Abstract]
Numerator: Net (loss) available to common shareholders	$ (21,844)	$ (209,189)	$ (1,300,010)	$ (340,311)
Denominator: Weighted average shares - basic and diluted	554,336	40,540	48,223	29,066
Net (loss) per share - basic and diluted	$ (0.04)	$ (5.16)	$ (26.95)	$ (11.71)

Advance from Shareholders (Deta

Advance from Shareholders (Details Narrative) - USD ($)	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Jul. 31, 2019
Proceeds of additional advances from shareholders	$ 174,284	$ 74,864
Repayments of advances received from shareholders	186,220	79,909
Advance from shareholders	63,886		$ 75,135
Shareholders [Member]
Proceeds of additional advances from shareholders	204,520
Repayments of advances received from shareholders	186,220
Advance from shareholders	0	$ 52,479	$ 75,135
Shareholders One [Member]
Proceeds of additional advances from shareholders	74,759
Repayments of advances received from shareholders	$ 63,133

Note Payable - Related Party (D

Note Payable - Related Party (Details Narrative) - USD ($)	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Jul. 31, 2019	Jan. 31, 2019	Aug. 31, 2013	Jan. 31, 2013
Promissory note					$ 489	$ 484,029
Interest rate, percentage				4.00%
Debt instrument, maturity date	Jan. 31, 2020
Payments on related party note payable	$ 9,456
Note payable related party	375,597		$ 435,894
Interest expense	64,013	$ 258,741
Series A Convertible Preferred Stock [Member]
Preferred stock exchange value on note	$ 50,000
Pre-Split [Member]
Shares issued during period	5,000
Post-Split [Member]
Shares issued during period	500

Capital Stock (Details Narrativ

Capital Stock (Details Narrative)	Apr. 08, 2020shares	Jan. 31, 2020USD ($)	Oct. 31, 2019	Feb. 25, 2019USD ($)$ / sharesshares	Apr. 30, 2020USD ($)$ / sharesshares	Oct. 31, 2019shares	Apr. 30, 2019USD ($)shares	Apr. 30, 2020USD ($)$ / sharesshares	Apr. 30, 2019USD ($)shares	Feb. 07, 2020shares	Jul. 31, 2019USD ($)$ / sharesshares	Mar. 01, 2019USD ($)
Common stock, shares issued					1,056,700			1,056,700			44,333
Common stock, shares outstanding					1,056,700			1,056,700			44,333
Convertible promissory note principal amount | $					$ 26,225			$ 26,225			$ 33,000
Reverse split stock, description								Reverse stock split on a 1:100,000 basis.
Loss on settlement of debt | $					$ 332,592			$ 262,592	$ 15,042
Stock-based compensation | $								$ 1,081,000	$ 36,249
Series F Convertible Preferred Stock [Member]
Preferred stock par value | $ / shares					$ 0.001			$ 0.001			$ 0.001
Preferred stock, authorized					40,000,000			40,000,000			40,000,000
Preferred stock, shares issued					0			0			0
Preferred stock, shares outstanding					0			0			0
Series T Convertible Preferred Stock [Member]
Preferred stock par value | $ / shares					$ 0.001			$ 0.001			$ 0.001
Preferred stock, authorized					375			375			375
Preferred stock, shares issued					0			0			0
Preferred stock, shares outstanding					0			0			0
Series B Super Voting Preferred Stock [Member]
Preferred stock par value | $ / shares					$ 0.001			$ 0.001
Preferred stock, authorized					1,000,000			1,000,000
Stock issued during period share compensation								1,000,000
Series G Convertible Preferred Stock [Member]
Preferred stock par value | $ / shares					$ 0.001			$ 0.001
Preferred stock, authorized					60,000			60,000
Series L Convertible Preferred Stock [Member]
Preferred stock par value | $ / shares					$ 0.001			$ 0.001			$ 0.001
Preferred stock, authorized					20			20			20
Stock issued during period share compensation								18
Stock issued during period share compensation, value | $								$ 1,940
Preferred stock, shares issued					18			18			0
Preferred stock, shares outstanding					18			18			0
Series G Shares [Member]
Converted shares								1,000
Outstanding shares of common stock, percentage								4.99%
Series A Convertible Preferred Stock [Member]
Preferred stock par value | $ / shares					$ 0.001			$ 0.001			$ 0.001
Preferred stock, authorized					1,950			1,950			1,950
Conversion of stock, description			Each share of Series A Preferred is convertible into 24 shares of common stock.
Liquidation description			In the event of any liquidation, dissolution, winding-up or sale or merger of the Company, whether voluntarily or involuntarily, each holder of Preferred Stock is entitled to receive, in preference to the holders of common stock, a per-share amount equal to the original issue price of $0.001 (as adjusted, as defined), plus all declared but unpaid dividends.
Preferred stock redemption description								The "Mandatory Redemption Price" shall be equal to the Liquidation Preference of the Preferred Shares being redeemed multiplied by one hundred and twenty five percent (125%) in same day funds.
Preferred stock, shares issued					1			1			0
Preferred stock, shares outstanding					1			1			0
Series A Preferred Stock [Member]
Stock issued during the period converted
Converted shares								3,300
Preferred stock, shares issued					5,000			5,000
Preferred stock, shares outstanding					1,700			1,700			0
Series A Convertible Preferred Stock [Member]
Issued shares of common stock								500
Issued shares of common stock, value | $								$ 120,000
Series A Convertible Preferred Stock [Member]
Issued shares of common stock								4,500
Issued shares of common stock, value | $								$ 1,080,000
Series B Super Voting Preferred Stock [Member]
Preferred stock par value | $ / shares					$ 0.001			$ 0.001
Preferred stock, authorized					1,000,000			1,000,000
Liquidation description								In the event of any liquidation, dissolution, winding-up or sale or merger of the Company, whether voluntarily or involuntarily, each holder of Preferred Stock is entitled to receive, in preference to the holders of common stock, a per-share amount equal to the original issue price of $0.001 (as adjusted, as defined), plus all declared but unpaid dividends.
Preferred stock voting rights								The Certificate of Designation, the Company authorized 1,000,000 shares of the Series B Super Voting Preferred Stock, which shall have non-dilutable voting rights equivalent to 68% of all voting shares.
Series L Convertible Preferred Stock [Member]
Preferred stock par value | $ / shares					$ 0.001			$ 0.001
Issued shares of common stock								1,940,000
March 25, 2020 [Member] | Settlement Agreement [Member] | Series G Shares [Member]
Stock issued during the period converted								1,500
January 17, 2019 [Member] | Series T Convertible Preferred Stock [Member]
Preferred stock par value | $ / shares					$ 0.001			$ 0.001
Preferred stock, authorized					375			375
Liquidation description								In the event of any liquidation, dissolution, winding-up or sale or merger of the Company, whether voluntarily or involuntarily, each holder of Preferred Stock is entitled to receive, in preference to the holders of common stock, a per-share amount equal to the original issue price of $0.001 (as adjusted, as defined), plus all declared but unpaid dividends.
Preferred stock redemption description								The "Mandatory Redemption Price" shall be equal to the Liquidation Preference of the Preferred Shares being redeemed multiplied by one hundred and twenty five percent (125%) in same day funds.
January 17, 2019 [Member] | Series L Convertible Preferred Stock [Member]
Preferred stock par value | $ / shares					$ 0.001			$ 0.001
Preferred stock, authorized					20			20
Liquidation description								In the event of any liquidation, dissolution, winding-up or sale or merger of the Company, whether voluntarily or involuntarily, each holder of Preferred Stock is entitled to receive, in preference to the holders of common stock, a per-share amount equal to the original issue price of $0.001 (as adjusted, as defined), plus all declared but unpaid dividends.
Preferred stock redemption description								The "Mandatory Redemption Price" shall be equal to the Liquidation Preference of the Preferred Shares being redeemed multiplied by one hundred and twenty five percent (125%) in same day funds.
February 7, 2020 [Member] | Series F Convertible Preferred Stock [Member]
Preferred stock, authorized					40,000,000			40,000,000
Outstanding shares of common stock, percentage								4.99%
Preferred stock, shares outstanding					10,000			10,000
Converted shares ratio								0.97
27 Health, Inc. [Member]
Ownership interest										100.00%
27 Health, Inc. [Member] | Series F Convertible Preferred Stock [Member]
Issued shares of common stock								10,000
27 Health, Inc. [Member] | Preferred Series F [Member]
Preferred stock, authorized										10,000
27 Health, Inc. [Member] | Series B Super Voting Preferred Stock [Member]
Issued shares of common stock								1,000,000
Auctus Fund LLC [Member]
Issued shares of common stock									1,103
Convertible promissory note principal amount | $							3,516		$ 3,516
Interest | $							$ 83		83
Penalty fees | $									$ 10,000
Auctus Fund LLC [Member] | August 1, 2018 [Member]
Issued shares of common stock								2,048
Auctus Fund LLC [Member] | August 1, 2018 [Member]
Convertible promissory note principal amount | $					$ 2,917			$ 2,917
Interest | $					4,776			4,776
Fees | $					$ 500			$ 500
Veyo Partners [Member] | Consulting Agreement [Member]
Fair value of common stock, shares reserved | $		$ 8,647
Veyo Partners [Member] | November 30, 2017 [Member] | Consulting Agreement [Member]
Common stock reserved							217		217
CNLT LLC [Member] | Series G Convertible Preferred Stock [Member]
Converted shares								550
Converted share amount | $								$ 50,000
CNLT LLC [Member] | March 25, 2020 [Member] | Series G Convertible Preferred Stock [Member]
Converted shares								550
Converted share amount | $								$ 330,000
JA Ventures, Inc [Member]
Stock issued during period share compensation								1,000,000
Crown Bridge Partners, LLC [Member]
Convertible promissory note principal amount | $				$ 165,000								$ 33,000
Warrants to purchase common stock				18,857,142
Exercise price of warrants | $ / shares				$ 0.0035
Warrant expiration date				Feb. 25, 2024
Fair value of warrants | $				$ 47,063
Preferred Stock [Member]
Preferred stock par value | $ / shares					$ 0.001			$ 0.001
Series A Convertible Preferred Stock [Member] | November 8, 2019 [Member]
Stock issued during the period converted								1,780
Series A Convertible Preferred Stock [Member] | November 13, 2019 [Member]
Non controlling interest rate					100.00%			100.00%
Common Stock [Member]
Stock issued during the period converted					4,000
Number of treasury shares returned								45,008
Common Stock [Member] | November 13, 2019 [Member]
Non controlling interest rate					51.16%			51.16%
Warrant [Member]
Number of warrants, granted during period
Number of warrants, forfeited during period
Number of warrants, expired or cancelled during period
Class of warrant or right, outstanding					189			189
Weighted average exercise price of warrants | $ / shares								$ 350
Warrants, weighted average remaining years								4 years
Warrants intrinsic value | $					$ 0			$ 0
Warrant [Member] | Crown Bridge Partners, LLC [Member]
Warrants to purchase common stock				189
Exercise price of warrants | $ / shares				$ 350
Warrant expiration date				Feb. 25, 2024
Fair value of warrants | $				$ 47,063
Carmine T. Biscardi [Member] | Common Stock [Member] | November 8, 2019 [Member]
Stock issued during the period converted								42,720
Chief Executive Officer [Member] | Series A Convertible Preferred Stock [Member]
Preferred stock, authorized					500			500
Stock issued during period share compensation								4,500
Converted share amount | $								$ 50,000
Convertible preferred stock, description								We determined the fair value of the preferred stock as of the issuance date based on the market price of $10 for common stock with 1 share of Series A Preferred Stock convertible to 24 shares of common stock, resulting in a fair value of $240 per share.
Loss on settlement of debt | $								$ 70,000
Stock-based compensation | $								$ 1,080,000
Chief Executive Officer [Member] | Series A Preferred Stock [Member]
Preferred stock, authorized					5,000			5,000
Two Investors [Member] | Series T Convertible Preferred Stock [Member]
Issued shares of common stock	4,000							1,333

Distribution Agreements (Detail

Distribution Agreements (Details Narrative)	Mar. 02, 2020USD ($)Days	Aug. 02, 2018USD ($)Days$ / shares	Apr. 30, 2020USD ($)	Jul. 31, 2019USD ($)	Jan. 31, 2019
Distribution agreement description			The Company's predecessor, Bigfoot, entered into a Distribution Agreement on September 2, 2011 with the Bosko Group LLC providing them a non-exclusive right to market the sales of the Company's DVD's. The Distribution Agreement requires the Company to pay the Bosko Group LLC ten percent (10%) of the selling price of the DVD's sold. This agreement remained in effect for a period of 4 years and has been automatically renewed for an additional 4 years with no limit on the number of times the agreement may be automatically renewed, unless either party gives notice to the other of its desire to terminate the Agreement at least sixty (60) days before expiration of the original or renewal term.
Convertible promissory note, face amount			$ 26,225	$ 33,000
Convertible promissory note, maturity date			Jan. 31, 2020
Convertible promissory note, interest rate					4.00%
Securities Purchase Agreement [Member] | August 2018 Note [Member]
Convertible promissory note, face amount			$ 79,399
Convertible promissory note, interest rate			24.00%
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member]
Aggregate purchase price	$ 110,000
Lowest sale price percentage	55.00%
Number of consecutive trading days | Days	20
Securities Purchase Agreement [Member] | Investor [Member] | August 2018 Note [Member]
Convertible promissory note, face amount		$ 110,000
Cash		100,000
Issuance cost of debt		$ 10,000
Convertible promissory note, maturity date		May 1, 2019
Convertible promissory note, interest rate		10.00%
Securities Purchase Agreement [Member] | Investor [Member] | Convertible Promissory Note [Member]
Aggregate purchase price		$ 100,000
Lowest sale price percentage		55.00%
Number of consecutive trading days | Days		20
Debt conversion converted amount		$ 15,000
Securities Purchase Agreement [Member] | Investor [Member] | Second August 2018 Note [Member] | Maximum [Member]
Conversion price per share | $ / shares		$ 0.01

Convertible Debt (Details Narra

Convertible Debt (Details Narrative)	Mar. 31, 2020shares	Mar. 02, 2020USD ($)Days	Sep. 23, 2019USD ($)shares	Feb. 25, 2019USD ($)Days$ / sharesshares	Apr. 30, 2020USD ($)Daysshares	Apr. 30, 2019USD ($)	Apr. 30, 2020USD ($)shares	Apr. 30, 2019USD ($)shares	Jul. 31, 2019USD ($)shares	Mar. 01, 2019USD ($)	Jan. 31, 2019
Principal amount					$ 26,225		$ 26,225		$ 33,000
Debt instrument, maturity date							Jan. 31, 2020
Debt instrument, interest rate											4.00%
Amortization of debt discount							$ 25,329	$ 197,807
(Gain) loss on derivative liability						$ 40,657	(18,578)	(151,196)
Proceeds from convertible promissory note							$ 410,448	155,500
Series G Convertible Preferred Stock [Member]
Number of common stock shares issued | shares	550
Preferred stock, shares authorized | shares					60,000		60,000		60,000
Convertible Promissory Note [Member] | Securities Purchase Agreement [Member]
Aggregate purchase price		$ 110,000
Proceeds from convertible promissory note		$ 110,000
Lowest sale price percentage		55.00%
Number of consecutive trading days | Days		20
March 2020 Note [Member] | Securities Purchase Agreement [Member]
Principal amount		$ 125,000
Debt instrument, maturity date		Jan. 2, 2021
Debt instrument, interest rate		12.00%
Issuance cost of debt		$ 10,000
KinerjaPay Corp [Member] | Convertible Promissory Note [Member]
Principal amount			$ 20,000
Debt instrument, maturity date			Mar. 23, 2020
Debt instrument, interest rate			10.00%
Common stock conversion rate			50.00%
Number of common stock shares issued | shares			50,000
KinerjaPay Corp [Member] | Convertible Promissory Note [Member] | Series G Convertible Preferred Stock [Member]
Preferred stock, shares authorized | shares			1,500
Crown Bridge Partners, LLC [Member]
Principal amount				$ 165,000						$ 33,000
Debt instrument, maturity date				Feb. 29, 2020
Debt instrument, interest rate				8.00%
Common stock conversion rate				50.00%
Fair value of derivative liability, conversion feature				$ 56,216
Amortization of debt discount				28,500
(Gain) loss on derivative liability				$ 27,716
Warrants to purchase common stock | shares				18,857,142
Weighted average exercises price of warrants | $ / shares				$ 0.0035
Warrant expiration date				Feb. 25, 2024
Fair value of warrants				$ 47,063
Number of consecutive trading days | Days				25
Crown Bridge Partners, LLC [Member] | CBP Warrants [Member]
Warrants to purchase common stock | shares				18,857,142
Weighted average exercises price of warrants | $ / shares				$ 0.0035
Warrant expiration date				Feb. 25, 2024
Fair value of warrants				$ 47,063
Crown Bridge Partners, LLC [Member] | First Installment [Member]
Principal amount				28,500
Crown Bridge Partners, LLC [Member] | CBP Notes [Member]
Principal amount				$ 165,000						$ 33,000
Debt instrument, maturity date				Feb. 29, 2020
Debt instrument, interest rate				8.00%
Common stock conversion rate				50.00%
Fair value of derivative liability, conversion feature				$ 56,216
Amortization of debt discount				28,500
(Gain) loss on derivative liability				$ 27,716
Number of consecutive trading days | Days				25
Crown Bridge Partners, LLC [Member] | CBP Notes [Member] | First Installment [Member]
Principal amount				$ 28,500
Auctus Fund LLC [Member]
Principal amount						$ 3,516		$ 3,516
Number of common stock shares issued | shares								1,103
Auctus Fund LLC [Member] | Third-Party Accredited Investor [Member]
Principal amount					$ 155,000		$ 155,000
Common stock conversion rate					40.00%		40.00%
Amortization of debt discount							$ 45,936	$ 120,438
Number of consecutive trading days | Days					20
Debt instrument, unamortized discount					$ 0		$ 0

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)

Jun. 18, 2020USD ($)Days$ / sharesshares

May 05, 2020shares

Mar. 31, 2020shares

Jun. 30, 2020shares

May 31, 2020USD ($)shares

Apr. 30, 2020USD ($)$ / sharesshares

May 20, 2020USD ($)

May 15, 2020USD ($)

Jul. 31, 2019USD ($)$ / sharesshares

Mar. 01, 2019USD ($)

Feb. 25, 2019USD ($)

Jan. 31, 2019

Principal amount | $

$ 26,225

$ 33,000

Debt instrument, interest rate

4.00%

Common stock, shares issued

1,056,700

44,333

Common stock, par value | $ / shares

$ 0.001

$ 0.001

Series G Convertible Preferred Stock [Member]

Number of common stock shares issued

550

Series G Shares [Member]

Shares issued for conversion

1,000

Crown Bridge Partners, LLC [Member]

Principal amount | $

$ 33,000

$ 165,000

Debt instrument, interest rate

8.00%

CNLT LLC [Member] | Series G Convertible Preferred Stock [Member]

Shares issued for conversion

550

Subsequent Event [Member] | Series G Convertible Preferred Stock [Member]

Shares issued for conversion

1,000

Common stock outstanding shares percentage

4.99%

Subsequent Event [Member] | Series G Convertible Preferred Stock [Member] | Maximum [Member]

Shares issued for conversion

3,000,000

Subsequent Event [Member] | 27Health [Member]

Net revenues from sales percentage

75.00%

After net revenues from sales percentage

65.00%

Subsequent Event [Member] | Coviguard or Lisa Marie Kao [Member]

Net revenues from sales percentage

25.00%

After net revenues from sales percentage

35.00%

Subsequent Event [Member] | Lisa Marie Kao [Member]

Debt instrument, interest rate

75.00%

Stock issued during period, value | $

$ 1,000,000

Stock issued during period, value, restricted shares | $

$ 1,000,000

Trading days | Days

20

Subsequent Event [Member] | Settlement Agreement [Member]

Number of common stock shares issued

50,000

Unpaid interest and penalties | $

$ 50,000

Subsequent Event [Member] | Settlement Agreement [Member] | Series G Convertible Preferred Stock [Member]

Shares issued for conversion

1,000

Number of common stock shares issued

1,500

Subsequent Event [Member] | Settlement Agreement [Member] | KPAY [Member]

Number of common stock shares issued

50,000

Subsequent Event [Member] | Coviguard Agreement [Member] | 27Health [Member]

Payments to acquire investment | $

$ 100,000

Initial advance an investment | $

$ 20,000

Common stock, shares issued

1,000,000

Common stock, par value | $ / shares

$ 0.001

Subsequent Event [Member] | Crown Bridge Partners, LLC [Member]

Shares issued for conversion

55,500

6,000

Subsequent Event [Member] | Lord Global Corporation [Member] | Definitive Agreement [Member]

Principal amount | $

$ 250,000

Debt instrument term

12 months

Debt instrument, interest rate

4.99%

Shares issued for conversion

2,000,000

Debt conversion instrument rate

50.00%

Subsequent Event [Member] | Lord Global Corporation [Member] | Definitive Agreement [Member] | Independent Contractors [Member]

Debt instrument, interest rate

10.00%

Subsequent Event [Member] | eWellness Healthcare Corporation [Member]

Principal amount | $

$ 250,000

Debt instrument, interest rate

20.00%

Repayment percentage

150.00%

Subsequent Event [Member] | eWellness Healthcare Corporation [Member] | Definitive Agreement [Member]

Debt instrument term

1 year

Debt instrument, interest rate

25.00%

Subsequent Event [Member] | Auctus Fund LLC [Member]

Shares issued for conversion

54,355

Subsequent Event [Member] | Auctus Fund LLC [Member] | Preferred Stock Conversion Option [Member]

Shares issued for conversion

58,200

Subsequent Event [Member] | CNLT LLC [Member] | Series G Convertible Preferred Stock [Member]

Number of common stock shares issued

950

Subsequent Event [Member] | CNLT LLC [Member] | Series G Shares [Member]

Number of common stock shares issued

1,500

Subsequent Event [Member] | KinerjaPay Corp [Member] | Preferred Series B [Member]

Number of common stock shares issued

1,500

Subsequent Event [Member] | United States Small Business Administration [Member]

Principal amount | $

$ 150,000

Debt instrument term

30 years

Debt instrument, description

Terms of the SBA Loan are approximately $150,000 principal repaid over 30 years at approximately a 3% fixed interest rate.

Debt instrument, interest rate

3.00%